You are here

Article Text

Article menu
Download PDFPDF
Clinical science
Ocular adnexal lymphoma: validation of American Joint Committee on Cancer seventh edition staging guidelines
  1. Matthew C Sniegowski1,
  2. Dianna Roberts2,
  3. Mathieu Bakhoum1,3,
  4. Peter Mc Laughlin4,
  5. Vivian T Yin1,
  6. Francesco Turturro4,
  7. Bita Esmaeli1
  1. 1Orbital Oncology and Ophthalmic Plastic and Reconstructive Surgery, Department of Plastic Surgery, Houston, Texasx, USA
  2. 2Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  3. 3The University of Texas Medical Branch at Galveston, Galveston, Texas, USA
  4. 4Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  1. Correspondence to Dr Bita Esmaeli, Orbital Oncology and Ophthalmic Plastic and Reconstructive Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1488, Houston, Texas 77030, USA; besmaeli{at}mdanderson.org

Abstract

Background/aims To validate the prognostic significance of the American Joint Committee on Cancer (AJCC) seventh edition staging criteria for ocular adnexal lymphoma (OAL) of all histologic subtypes.

Methods Retrospective review of clinical records for all consecutive patients with OAL treated from November 1998 to December 2012.

Results 130 patients were evaluated, 82 with primary and 34 with secondary OAL. Fourteen patients were excluded due to incomplete records. 71 women (61.2%) and 45 men (38.8%) had a median age of 61.5 years. Patients were followed for a median of 32.5 months. Treatment varied, in part, related to lymphoma histologic subtype. Overall, there were 17 recurrences (8 local and 9 distant) in patients with primary OAL. For primary OAL, the 5-year disease-free survival (DFS) and overall survival (OS) rates were 55.9% and 85.8%, respectively. For primary OAL, while there was a trend towards decreased 5-year DFS for more aggressive subtypes, this was not statistically significant. More advanced Ann Arbor stage was associated with decreased 5-year DFS; however, this trend was not statistically significant. However, increased AJCC seventh edition T category was associated with decreased 5-year DFS (T1=67.8%, T2=59.2%, T3=28.6%, T4=33.3%; p=0.025).

Conclusion AJCC seventh edition T category was predictive of DFS in patients with OAL.

  • Orbit
  • Neoplasia

https://doi.org/10.1136/bjophthalmol-2013-304847

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text